United States: Worried That Hospital Is Getting Off Too Easy, Judge Refuses To OK Settlement

Last Updated: February 25 2013

Article by Nina Youngstrom

A federal judge on Jan. 17 nixed a proposed settlement of criminal and civil allegations against WakeMed Health & Hospitals in Raleigh, N.C., causing a stir in the world of fraud negotiations.

U.S. District Judge Terrence Boyle set another hearing for Feb. 5 to determine the fate of a deal that the U.S. Attorney's Office for the Eastern District of North Carolina struck with WakeMed, which was accused of submitting inpatient claims for procedures that were performed in an outpatient setting (RMC 12/24/12, p. 1). WakeMed had agreed to pay $8 million and comply with a deferred prosecution agreement. If all goes well, prosecutors will drop the criminal charges after two years.

That did not sit well with the judge. "It's very difficult for society and the court to differentiate between the everyday working Joe or Jane who goes to prison and the nonprofit corporate giant who doesn't go to jail, who gets a slap on the hand and doesn't miss a beat," Boyle said, according to a report in the Raleigh News & Observer. The agreement, the judge said, seems like a "slap on the hand" for a "too big to fail" corporate giant. "Why not take a guilty plea, defer imposition of the judgment and sentence, and come back in two years and take a post hoc dismissal?" the newspaper reported the judge saying. (A transcript of the hearing was not available by press time.)

The judge's comments were unusual on procedural grounds alone, says former federal prosecutor Richard Westling, now with Waller Lansden in Nashville. The Federal Rules of Evidence (Rule 11(c)) allow judges to accept or reject a plea agreement, "but he is not supposed to dictate the terms," Westling says. "Typically, the judge doesn't participate."

But a more seismic change may be under way. "This is the kind of development that will cause lawyers representing health care companies to think long and hard about the way settlements are structured," Westling says. "If there is a substantial likelihood a judge will push back, it creates a huge challenge in the way that companies work to close their issues with the government and move on with their compliance obligations."

Another federal judge expressed misgivings after Pfizer Inc. paid $2.3 billion to resolve civil and criminal allegations of illegally promoting four drugs but no one was prosecuted. At Pfizer's sentencing in U.S. District Court in Boston, the judge complained that there was "no soul to condemn and no body to kick," according to federal prosecutor Jeremy Sternberg from the U.S. Attorney's Office (RMC 10/10/11, p. 1).

Will Future Investigations Be Influenced?

What's ironic about the WakeMed drama is it may have a chilling effect on the government's decision to include criminal allegations in cases against hospitals, Westling says. Although the judge may feel it's important to send a message that corporations shouldn't only pay fines but also face convictions, he may be perpetuating that outcome by creating uncertainty in the settlement process, Westling says. "One reason to use deferred prosecution agreements is [for the Department of Justice] to be tougher on entities by making it clear the conduct is criminal while recognizing the problems posed by a conviction. If you are going to be scared straight by the judge and told you need to whack these people more, does the government change its strategy? If so, what would that mean? Health care organizations are motivated to settle because they want closure and they want to go on with running their businesses and caring for patients with their new compliance obligations," Westling says. "Unpredictability about whether the court will accept a resolution that has been approved by the Department of Justice may make it harder to convince health care organizations that resolution is in their best interests."

The Department of Justice announced WakeMed's global resolution Dec. 19 in an unusual twist on short stays and medical necessity. The criminal information focused on WakeMed's 41-bed Health Center Observation Area, which had no licensed inpatient beds. Physicians never planned for patients to stay overnight as inpatients, but WakeMed billed Medicare for MS-DRGs anyway, the information alleged. Patient access staff allegedly disregarded or circumvented physicians' outpatient orders in the electronic database, and the hospital billed for cardiac patients as if they were inpatients even though they didn't remain in the hospital overnight.

Former federal prosecutor Robert Trusiak says the judge's actions show, again, that "the judiciary plays an active role, not a passive role, in global resolutions." Boyle's comments and his refusal to approve the settlement, at least for now, are consistent with the central theme of the Department of Justice's 2003 "Thompson memorandum," which addresses prosecutions of businesses. Written by then-Deputy Attorney General Larry Thompson, the memo requires prosecutors to treat corporate persons the same as natural persons, says Trusiak, now senior counsel and chief compliance officer for Kaleida Health in Buffalo, N.Y. "If a prosecutor is going to seek to convict a bank embezzler of embezzling $10,000, then the policy requires equal vigor for corporate persons. That's my take on what the judge did."

Trusiak also has concerns about deferred prosecution agreements. "Prosecutions must vindicate two goals: punishment and deterrence. It is difficult to determine how deferred prosecution agreements vindicate either of those goals," he says.

Westling speculates on possible scenarios for WakeMed's Feb. 5 return to court:

  1. The benefits of the global resolution are presented and the judge will accept the deal. He says that WakeMed and the government may want to highlight the services that the hospital provides to the community, such as charity care, and explain the effect on the community of a criminal conviction and Medicare exclusion.
  2. Hospital officials show up in court this time. At the Jan. 17 hearing, the judge criticized WakeMed for not sending anyone but its lawyer, according to the News & Observer. As a result, no board member or top administrator could answer Boyle's questions. Westling says one strategy for the February hearing may be to have a high-level corporate representative attend, prepared to accept responsibility on behalf of the hospital. This could change the way the judge looks at the case, he says.
  3. Before the second hearing, WakeMed and the government could agree to make the settlement more punitive by increasing the amount of money WakeMed has to pay or extending the length of the deferred prosecution agreement from two years to perhaps five years, which is the length of the corporate integrity agreement that is also required in the global resolution. The judge may find the global resolution more palatable, Westling says.

Whatever happens, the debate rages on among enforcers and Medicare watchdogs about the best way to enforce the laws. More prosecutions of individuals versus corporations? Some U.S. attorneys believe that pursuing corporations is the way to go. But, Westling notes, "lately the Justice Department, OIG and Congress have been pointing out the number of recidivist corporations. The government believes that corporate misconduct only occurs because people do it. Clearly, enforcers are weighing whether it's time to go back to bodies and souls."

Previously published in AIS Health

For further information visit Waller

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.